Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats

Pharmacology Biochemistry and Behavior

Volumn 94, Issue 2, 2009, Pages 219-226

  Gupta, Amit ^a   Dhir, Ashish ^a   Kumar, Anil ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Catatonia; Cyclooxygenase enzyme; Neuroprotection; Oxidative stress; Parkinson's disease (PD); Perphenazine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CELECOXIB; LIPID PEROXIDE; NAPROXEN; NIMESULIDE; NITRITE; PERPHENAZINE; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN PROTECTION; CATATONIA; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG DOSE COMPARISON; LOCOMOTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; CATATONIA; CORPUS STRIATUM; CYCLOOXYGENASE INHIBITORS; MALE; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PERPHENAZINE; RATS; RATS, WISTAR;

RATTUS;

EID: 72049098787     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.07.018     Document Type: Article

References (53)

1. Akula K.K., Dhir A., and Kulkarni S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res 78 (2008) 60-70
2. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989) 366-375
3. Arzi A., and Rezaei M. The effect of oral administration of L-tyrosine, floic acid and pyridoxine on perphenazine-induced catatonia in rat. Iran J Pharm Res 2 (2003) 167-171
4. Asanuma M., Miyazaki I., Tsuji T., and Ogawa N. New aspects of neuroprotective effects of nonsteroidal anti-inflammatory drugs. Nihon Shinkei Seishin Yakurigaku Zasshi 23 (2003) 111-119
5. Aubin N., Curet O., Deffois A., and Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71 (1998) 1635-1642
6. Bartels A.L., and Leenders K.L. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 22 (2007) 1852-1856
7. Bird J.E., Milhoan K., Wilson C.B., Young S.G., Mundy C.A., Parthasarathy S., et al. Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction. J Clin Invest 81 (1988) 1630-1638
8. Bornebroek M., de Lau L.M., Haag M.D., Koudstaal P.J., Hofman A., Stricker B.H., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28 (2007) 193-196
9. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362 (1997) 77-86
10. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willet W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch Neurol 60 (2003) 1059-1064
11. Cohen G., and Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249 (1974) 2447-2452
12. Dhir A., Naidu P.S., and Kulkarni S.K. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict Biol 10 (2005) 329-335
13. Dhir A., Naidu P.S., and Kulkarni S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 16 (2007) 691-697
14. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 82 (1959) 70-77
15. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205 (2007) 295-312
16. Etminan M., Carleton B.C., and Samii A. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 15 (2008) 576-577
17. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 252 Suppl 4 (2005) IV37-IV42
18. Ferger B., Spratt C., Teismann P., Seitz G., and Kuschinsky K. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 360 (1998) 155-163
19. Gerlach M., Blum-Degen D., Lan J., and Riederer P. Nitric oxide in the pathogenesis of Parkinson's disease. Adv Neurol 80 (1999) 239-245
20. Gu M., Owen A.D., Toffa S.E., Cooper J.M., Dexter D.T., Jenner P., et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 158 (1998) 24-29
21. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64 (1995) 919-924
22. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099
23. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A 94 (1997) 7531-7536
24. Khanna N.K., and Madan B.R. Effects of some beta-adrenoceptor antagonists on oxotremorine induced tremor: physostigmine induced lethality and perphenazine induced catatonia. Indian J Pharmacol 1 (1975) 14-21
25. Kim Y.S., and Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38 (2006) 333-347
26. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186 (1978) 189-195
27. Kulkarni S.K., Arzi A., and Kaul P.N. Modification of drug-induced catatonia and tremors by quapazine in rats and mice. Jpn J Pharmacol 30 (1980) 129-135
28. Lizasoain I., Moro M.A., Knowles R.G., Darley-Usmar V., and Moncada S. Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Biochem J 314 Pt 3 (1996) 877-880
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
30. Martins M.R., Petronilho F.C., Gomes K.M., Dal-Pizzol F., Streck E.L., and Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox Res 13 (2008) 63-69
31. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63 (2004) 901-910
32. Montastruc J.L., Rascol O., and Senard J.M. New directions in the drug treatment of Parkinson's disease. Drugs Aging 9 (1996) 169-184
33. Mosley R.L., Benner E.J., Kadiu I., Thomas M., Boska M.D., Hasan K., et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin Neurosci Res 6 (2006) 261-281
34. Naidu P.S., and Kulkarni S.K. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 819-822
35. Neusch C., Böhme V., Riesland N., Althaus M., and Moser A. The dopamine D2 receptor agonist alpha-dihydroergocryptine modulates voltage-gated sodium channels in the rat caudate-putamen. J Neural Transm 107 (2000) 531-541
36. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 (1979) 351-358
37. Okuno T., Nakatsuji Y., Kumanogoh A., Moriya M., Ichinose H., Sumi H., et al. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease. J Neurosci Res 81 (2005) 874-882
38. Paxinos G., Watson C., Pennisi M., and Topple A. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods 13 (1985) 139-143
39. Penn M.S. The role of leukocyte-generated oxidants in left ventricular remodeling. Am J Cardiol 101 (2008) 30D-33D
40. Polydoro M., Schroder N., Lima M.N., Caldana F., Laranja D.C., Bromberg E., et al. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78 (2004) 751-756
41. Raghavendra V., Agrewala J.N., and Kulkarni S.K. Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol 395 (2000) 15-21
42. Reksidler A.B., Lima M.M., Zanata S.M., Machado H.B., da Cunha C., Andreatini R., et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560 (2007) 163-175
43. Rojas P., Serrano-Garcia N., Mares-Samano J.J., Medina-Campos O.N., Pedraza-Chaverri J., and Ogren S.O. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci 28 (2008) 41-50
44. Sanchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A.L., and Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 1 (2004) 6
45. Singh A., and Kulkarni S.K. Role of adenosine in drug-induced catatonia. Indian J Exp Biol 40 (2002) 882-888
46. Singh A., Naidu P.S., and Kulkarni S.K. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats. Indian J Exp Biol 41 (2003) 1264-1268
47. Slivka A., and Cohen G. Hydroxyl radical attack on dopamine. J Biol Chem 260 (1985) 15466-15472
48. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134 (2005) 57-66
49. Sweet R.D., McDowell F.H., Wasterlain C.G., and Stern P.H. Treatment of "on-off effect" with a dopa decarboxylase inhibitor. Arch Neurol 32 (1975) 560-563
50. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
51. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100 (2003) 5473-5478
52. Vijitruth R., Liu M., Choi D.Y., Nguyen X.V., Hunter R.L., and Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 3 (2006) 6
53. Watanabe Y., Kato H., and Araki T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metab Brain Dis 23 (2008) 51-69